FGAM
TAK icon

Financial Gravity Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Financial Gravity Asset Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7
Closed – – 1536
2019
Q2 		$0 Buy
+7
New +$127 ﹤0.01% 1644

Other funds holding TAK

GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Financial Gravity Asset Management's TAK Position: Q3 2019 in Review

Financial Gravity Asset Management sold out of Takeda Pharmaceutical (TAK) in Q3 2019, closing a stake of 7 shares.

Financial Gravity Asset Management first reported a position in TAK in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • Financial Gravity Asset Management reported no remaining Takeda Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Financial Gravity Asset Management sold 7 Takeda Pharmaceutical shares in Q3 2019.
  • Financial Gravity Asset Management first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 1 quarter.
  • Financial Gravity Asset Management's Takeda Pharmaceutical position peaked at $0 in Q2 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on Financial Gravity Asset Management's 13F filing for Q3 2019, filed 15 Oct 2019.